Iqvia Holdings Inc (NYSE:IQV) – Equities researchers at William Blair cut their Q1 2018 earnings estimates for Iqvia in a report issued on Thursday, Zacks Investment Research reports. William Blair analyst J. Kreger now forecasts that the medical research company will earn $0.69 per share for the quarter, down from their previous estimate of $1.24. William Blair also issued estimates for Iqvia’s Q2 2018 earnings at $0.71 EPS, Q3 2018 earnings at $0.79 EPS, Q4 2018 earnings at $0.94 EPS, FY2018 earnings at $3.13 EPS, FY2019 earnings at $3.85 EPS and FY2020 earnings at $4.77 EPS.
Iqvia (NYSE:IQV) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.34 by ($0.02). Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the prior year, the firm posted $1.09 earnings per share. The business’s revenue was up 10.7% on a year-over-year basis.
Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Royal Bank of Canada set a $118.00 price objective on shares of Iqvia and gave the stock a “buy” rating in a report on Thursday, February 15th. Mizuho set a $97.00 price objective on shares of Iqvia and gave the stock a “hold” rating in a report on Wednesday, January 24th. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Zacks Investment Research cut shares of Iqvia from a “hold” rating to a “sell” rating in a research report on Tuesday, February 20th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $110.02.
Iqvia (NYSE:IQV) traded down $0.84 during midday trading on Monday, hitting $104.84. 1,111,427 shares of the stock were exchanged, compared to its average volume of 1,186,370. Iqvia has a 52 week low of $76.80 and a 52 week high of $110.67. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market cap of $22,062.05, a P/E ratio of 17.33, a P/E/G ratio of 2.71 and a beta of 0.64.
In other Iqvia news, Director Michael J. Evanisko sold 816 shares of the business’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $100.00, for a total value of $81,600.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $99.97, for a total transaction of $999,700.00. The disclosure for this sale can be found here. Insiders sold 30,816 shares of company stock worth $3,093,400 in the last 90 days. Corporate insiders own 6.00% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Iqvia during the fourth quarter valued at about $1,364,000. Colonial Trust Advisors purchased a new position in shares of Iqvia during the fourth quarter valued at about $5,550,000. Xact Kapitalforvaltning AB purchased a new position in shares of Iqvia during the fourth quarter valued at about $4,054,000. Envestnet Asset Management Inc. purchased a new position in shares of Iqvia during the fourth quarter valued at about $1,497,000. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp purchased a new position in shares of Iqvia during the fourth quarter valued at about $7,838,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.